<div class="body">
    <div class="content">
        <div class="fullText fullWidth">
            <div id="articleOutline">
                <h2>Article Outline</h2>
                <ol class="artOutline">
                    <li><a href="#sec1">Summary</a></li>
                    <li><a href="#cebib0010">References</a></li>
                </ol>
            </div>
            <div class="keywords">
                <h4>Abbreviations used in this paper:</h4>
                <a href="/action/doSearch?searchType=quick&amp;occurrences=all&amp;ltrlSrch=true&amp;searchScope=series&amp;searchText=AGA&amp;seriesISSN=0016-5085">AGA</a>                (<a href="/action/doSearch?searchType=quick&amp;occurrences=all&amp;ltrlSrch=true&amp;searchScope=series&amp;searchText=American Gastroenterological Association&amp;seriesISSN=0016-5085">American Gastroenterological Association</a>),
                <a href="/action/doSearch?searchType=quick&amp;occurrences=all&amp;ltrlSrch=true&amp;searchScope=series&amp;searchText=GRADE&amp;seriesISSN=0016-5085">GRADE</a>                (<a href="/action/doSearch?searchType=quick&amp;occurrences=all&amp;ltrlSrch=true&amp;searchScope=series&amp;searchText=Grading of Recommendations Assessment, Development and Evaluation&amp;seriesISSN=0016-5085">Grading of Recommendations Assessment, Development and Evaluation</a>)</div>
            <p>This document presents the official recommendations of the American Gastroenterological Association (AGA) Institute
                on the medical management of microscopic colitis. The guideline was developed by the AGA Clinical Guidelines
                Committee and approved by the AGA Governing Board. It is accompanied by a technical review that is a compilation
                of clinical evidence from which these recommendations were formulated.<span class="bibRef"><sup><a class="layerTrigger layerTriggerClick" href="javascript:void(0);" id="back-bib1">1</a></sup><span class="hoverLayer refLayer"><span aria-label="close window" class="closeBtn" role="button" tabindex="0">x</span>
                <span class="refLabel">1</span><span class="reference"><span class="refAuthors">Pardi, D.S., Tremaine, W.J., and Carrasco-Labra, A. </span>
                <span class="refTitle">American Gastroenterological Association institute technical review on the medical management of microscopic
                        colitis. </span><span class="refSeriesTitle">Gastroenterology</span>. <span class="refSeriesDate">2016</span>;
                <span class="refSeriesVolume">150</span>: <span class="refPages">247&ndash;274</span></span>
                </span>
                </span>
            </p>
            <p>Microscopic colitis is characterized by chronic watery diarrhea caused by inflammation in the colon and diagnosed
                by colonic biopsy. With a predilection for those 60 years of age or older, it comprises 2 subtypes, lymphocytic
                colitis and collagenous colitis; there is a female predominance in the latter. The reported prevalence of
                microscopic colitis ranges from 48 to 219 per 100,000.<span class="bibRef"><sup><a class="layerTrigger layerTriggerClick" href="javascript:void(0);" id="back-bib1">1</a></sup><span class="hoverLayer refLayer"><span aria-label="close window" class="closeBtn" role="button" tabindex="0">x</span>
                <span class="refLabel">1</span><span class="reference"><span class="refAuthors">Pardi, D.S., Tremaine, W.J., and Carrasco-Labra, A. </span>
                <span class="refTitle">American Gastroenterological Association institute technical review on the medical management of microscopic
                        colitis. </span><span class="refSeriesTitle">Gastroenterology</span>. <span class="refSeriesDate">2016</span>;
                <span class="refSeriesVolume">150</span>: <span class="refPages">247&ndash;274</span></span>
                </span>
                </span>
            </p>
            <p>Microscopic colitis is not associated with increased mortality, although symptoms can lead to impaired quality
                of life. Unlike other inflammatory colitides, there is no evidence that the persistence of histological inflammation
                portends long-term unfavorable outcomes such as colorectal cancer or need for surgery. Accordingly, the goal
                of medical therapy reflected in these recommendations is to relieve symptoms and improve quality of life
                while minimizing drug-related adverse effects. Because outcomes did not differ between lymphocytic colitis
                and collagenous colitis in the technical review, the recommendations in this guideline do not distinguish
                between subtypes of microscopic colitis.<span class="bibRef"><sup><a class="layerTrigger layerTriggerClick" href="javascript:void(0);" id="back-bib1">1</a></sup><span class="hoverLayer refLayer"><span aria-label="close window" class="closeBtn" role="button" tabindex="0">x</span>
                <span class="refLabel">1</span><span class="reference"><span class="refAuthors">Pardi, D.S., Tremaine, W.J., and Carrasco-Labra, A. </span>
                <span class="refTitle">American Gastroenterological Association institute technical review on the medical management of microscopic
                        colitis. </span><span class="refSeriesTitle">Gastroenterology</span>. <span class="refSeriesDate">2016</span>;
                <span class="refSeriesVolume">150</span>: <span class="refPages">247&ndash;274</span></span>
                </span>
                </span>
            </p>
            <p>This guideline focuses on the medical treatment of microscopic colitis and does not specifically address its
                diagnosis, surgical management, or the appropriateness of screening for associated autoimmune disorders.
                Because microscopic colitis occurs in 7.5% of patients undergoing evaluation for chronic diarrhea, it would
                be prudent when assessing these patients with endoscopy to perform colonoscopy with biopsies of multiple
                segments of the colon. If for any reason flexible sigmoidoscopy is performed instead of colonoscopy, it is
                important to obtain biopsy specimens from the descending colon in addition to those from the rectosigmoid
                colon because biopsy specimens from the latter may not reveal the disease in some cases. Moreover, when patients
                with microscopic colitis have ongoing symptoms despite medical therapy, coexisting causes of chronic diarrhea
                such as celiac disease should be considered. The persistence of residual bowel symptoms may also reflect
                coexisting or postinflammatory functional bowel disorders. Patients with refractory symptoms should also
                avoid potential medication triggers such as nonsteroidal anti-inflammatory drugs, proton pump inhibitors,
                and selective serotonin reuptake inhibitors.</p>
            <p>The guideline was developed using a process outlined elsewhere.<span class="bibRef"><sup><a class="layerTrigger layerTriggerClick" href="javascript:void(0);" id="back-bib2">2</a></sup><span class="hoverLayer refLayer"><span aria-label="close window" class="closeBtn" role="button" tabindex="0">x</span>
                <span class="refLabel">2</span><span class="reference">AGA Institute clinical practice guideline development process. <a href="http://www.gastro.org/guidelines/guidelines-policies">http://www.gastro.org/guidelines/guidelines-policies</a>.</span><br
                />
                <br />
                <a class="allReferencesLink" href="#references">See all References</a></span>
                </span><span class="hidden crossref-label"><span class="bib2">2</span></span> Briefly, the AGA process for developing
                clinical practice guidelines incorporates best practices of guideline development as outlined by the Institute
                of Medicine.<span class="bibRef"><sup><a class="layerTrigger layerTriggerClick" href="javascript:void(0);" id="back-bib3">3</a></sup><span class="hoverLayer refLayer"><span aria-label="close window" class="closeBtn" role="button" tabindex="0">x</span>
                <span class="refLabel">3</span><span class="reference"><span class="refAuthors">Graham, R., Mancher, M., Wolman, D.M. et al. </span>
                <span class="refTitle">Clinical practice guidelines we can trust. </span><span class="refPublisherName">Institute of Medicine; The National Academies Press</span>,
                <span class="refPublisherLoc">Washington, DC</span>; <span class="refDate">2011</span></span><br />
                <br />
                <a class="allReferencesLink" href="#references">See all References</a></span>
                </span><span class="hidden crossref-label"><span class="bib3">3</span></span> The Grading of Recommendations Assessment,
                Development and Evaluation (GRADE) approach was used to prepare the background summary of evidence, develop
                the technical review, and assess the certainty of the evidence and grade the strength of the recommendations.
                <span
                    class="bibRef"><sup><a class="layerTrigger layerTriggerClick" href="javascript:void(0);" id="back-bib4">4</a></sup>
                    <span
                        class="hoverLayer refLayer"><span aria-label="close window" class="closeBtn" role="button" tabindex="0">x</span>
                        <span class="refLabel">4</span><span class="reference"><span class="refAuthors">Sultan, S., Falck-Ytter, Y., and Inadomi, J.M. </span>
                        <span class="refTitle">The AGA Institute process for developing clinical practice guidelines part one: grading the
                                    evidence. </span><span class="refSeriesTitle">Clin Gastroenterol Hepatol</span>.
                        <span class="refSeriesDate">2013</span>; <span class="refSeriesVolume">11</span>: <span class="refPages">329&ndash;332</span></span>
                        </span>
                        </span>
            </p>
            <p>Optimal understanding of this guideline will be enhanced by reading applicable portions of the technical review.
                The guideline panel and the authors of the technical review met in person on April 25, 2015, to discuss the
                quality of evidence (<a class="figureLink" href="#tbl1" id="back-tbl1">Table&nbsp;1</a><span class="hidden crossref-label"><span class="tbl1">Table&nbsp;1</span></span>)
                and consider other factors relevant for the risk/benefit assessment of the recommendations. The guideline
                authors subsequently formulated the recommendations. Although quality of evidence was a cardinal factor in
                determining the strength of the recommendations (<a class="figureLink" href="#tbl2" id="back-tbl2">Table&nbsp;2</a>
                <span class="hidden crossref-label"><span class="tbl2">Table&nbsp;2</span></span>), the balance between benefit
                and harm, patients&rsquo; values and preferences, and resource utilization was also taken into consideration.</p>
            <div class="textbox shadow cRounded bgComment inner articleTextbox" id="dtbox1">
                <div class="caption">&nbsp;</div>
                <div class="textbox-body">
                    <div class="content">
                        <p><strong>Recommendation 1. In patients with symptomatic microscopic colitis, the AGA recommends treatment with budesonide over no treatment for the induction&nbsp;of clinical remission. <em>Strong recommendation, moderate quality of evidence.</em></strong></p>
                    </div>
                    <div class="textbox-tail">
                        <div class="referencesWrapper" id="">
                            <div id="references">&nbsp;</div>
                        </div>
                    </div>
                </div>
            </div>
            <p>&nbsp;</p>
            <div class="floatDisplay">
                <div class="table-wrap" id="tbl1">
                    <table>
                        <caption tabindex="0"><span class="label">Table&nbsp;1</span><span>GRADE Definitions of Quality of Evidence</span></caption>
                        <tbody>
                            <tr>
                                <td>High</td>
                                <td>We are very confident that the true effect lies close to that of the estimate of the effect.</td>
                            </tr>
                            <tr>
                                <td>Moderate</td>
                                <td>We are moderately confident in the effect estimate. The true effect is likely to be close
                                    to the estimate of the effect, but there is a possibility that it is substantially different.</td>
                            </tr>
                            <tr>
                                <td>Low</td>
                                <td>Our confidence in the effect estimate is limited. The true effect may be substantially different
                                    from the estimate of the effect.</td>
                            </tr>
                            <tr>
                                <td>Very low</td>
                                <td>We have very little confidence in the effect estimate. The true effect is likely to be substantially
                                    different from the estimate of effect</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </div>
            <div class="floatDisplay">
                <div class="table-wrap" id="tbl2">
                    <table>
                        <caption tabindex="0"><span class="label">Table&nbsp;2</span><span>GRADE Definitions of Strength of Recommendation</span></caption>
                        <tbody>
                            <tr>
                                <th scope="col">&nbsp;</th>
                                <th scope="col">For the patient</th>
                                <th scope="col">For the clinician</th>
                            </tr>
                            <tr>
                                <td>Strong</td>
                                <td>Most individuals in this situation would want the recommended course of action, and only
                                    a small proportion would not.</td>
                                <td>Most individuals should receive the recommended course of action. Formal decision aids are
                                    not likely to be needed to help individuals make decisions consistent with their values
                                    and preferences.</td>
                            </tr>
                            <tr>
                                <td>Conditional</td>
                                <td>The majority of individuals in this situation would want the suggested course of action,
                                    but many would not.</td>
                                <td>Different choices will be appropriate for different patients. Decision aids may well be useful
                                    in helping individuals making decisions consistent with their values and preferences.
                                    Clinicians should expect to spend more time with patients when working toward a decision.</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </div>
            <p>A meta-analysis of 6 randomized clinical trials showed clear benefit of budesonide in inducing clinical response,
                with 5 studies also showing histological response. Two studies also showed improvement in quality of life,
                although the difference did not reach statistical significance. Patients treated with 9 mg of budesonide
                daily were more than twice as likely to achieve clinical remission over an average of 7 to 13 days when compared
                with no treatment (relative risk, 2.52; 95% confidence interval, 1.45&ndash;4.4). The risk of serious adverse
                events is low with budesonide. Because of the highly favorable risk/benefit profile and convenience of once-daily
                dosing, budesonide should be considered first-line therapy for the treatment of microscopic colitis. However,
                because budesonide is expensive, alternative therapies may also be considered if cost is a determining factor.
                In general, it is not necessary to perform colonoscopy to assess histological response. However, for patients
                who have residual symptoms after treatment with budesonide, normal colonic biopsy specimens may be suggestive
                of coexisting irritable bowel syndrome or celiac disease. Cessation of budesonide can be considered after
                8 weeks of therapy. One-third of patients will remain symptom-free thereafter and not require maintenance
                therapy, which mitigates long-term cost issues with the drug.</p>
            <div class="textbox shadow cRounded bgComment inner articleTextbox" id="dtbox2">
                <div class="caption">&nbsp;</div>
                <div class="textbox-body">
                    <div class="content">
                        <p><strong>Recommendation 2. In patients with symptomatic microscopic colitis, the AGA recommends treatment with budesonide over mesalamine for the induction of clinical remission. <em>Strong recommendation, high quality of evidence.</em></strong></p>
                    </div>
                    <div class="textbox-tail">
                        <div class="referencesWrapper" id="">
                            <div id="references">&nbsp;</div>
                        </div>
                    </div>
                </div>
            </div>
            <p>&nbsp;</p>
            <p>A high-quality clinical trial provided direct evidence that budesonide should be considered first-line therapy
                over mesalamine whenever possible. Patients with symptomatic microscopic colitis who were treated with budesonide
                9 mg daily were nearly twice as likely as those treated with mesalamine 3 g daily to achieve clinical and
                histological remission, and there was no statistically significant difference in occurrence of adverse events.</p>
            <div class="textbox shadow cRounded bgComment inner articleTextbox" id="dtbox3">
                <div class="caption">&nbsp;</div>
                <div class="textbox-body">
                    <div class="content">
                        <p><strong>Recommendation 3. In patients with symptomatic microscopic colitis in whom budesonide therapy is not feasible, the AGA suggests treatment with mesalamine over no treatment for the induction of clinical remission. <em>Conditional recommendation, moderate quality of evidence.</em></strong></p>
                    </div>
                    <div class="textbox-tail">
                        <div class="referencesWrapper" id="">
                            <div id="references">&nbsp;</div>
                        </div>
                    </div>
                </div>
            </div>
            <p>Moderate-quality evidence from a single randomized clinical trial suggests that mesalamine therapy is associated
                with a lower likelihood of achieving clinical response when compared with no treatment (odds ratio, 0.74;
                95% confidence interval, 0.44&ndash;1.24), although this was not statistically significant. Thus, due to
                serious imprecision, the benefit of mesalamine in achieving clinical remission is uncertain. Although not
                directly comparable, it should be noted that in 2 other clinical trials in which mesalamine was administered
                in the control arm, the clinical response rate was 84% and 87%, while in a third it was 44%. Because of the
                uncertain balance between benefits and potential harms, mesalamine is recommended conditionally as a potential
                second-line therapy that can be used under select circumstances. A trial of mesalamine may be appropriate
                for patients who have a contraindication or had a poor response to budesonide or those who have a strong
                preference against using it. Because costs are similar between mesalamine and budesonide, it is not likely
                to be a determining factor.</p>
            <div class="textbox shadow cRounded bgComment inner articleTextbox" id="dtbox4">
                <div class="caption">&nbsp;</div>
                <div class="textbox-body">
                    <div class="content">
                        <p><strong>Recommendation 4. In patients with symptomatic microscopic colitis in whom budesonide therapy is not feasible, the AGA suggests treatment with bismuth salicylate over no treatment for the induction of clinical remission. <em>Conditional recommendation, low quality of evidence.</em></strong></p>
                    </div>
                    <div class="textbox-tail">
                        <div class="referencesWrapper" id="">
                            <div id="references">&nbsp;</div>
                        </div>
                    </div>
                </div>
            </div>
            <p>In a small randomized controlled trial of bismuth salicylate, all 7 patients in the intervention arm showed clinical
                response whereas none of the 7 patients in the control arm responded. Patients treated with bismuth salicylate
                had a 3-fold higher likelihood of achieving histological response, although this was not statistically significant.
                Due to serious imprecision, the clinical benefit from treatment was uncertain. Although there were no adverse
                events reported, it is unknown whether long-term treatment would be associated with salicylate or bismuth
                toxicity. Moreover, taking 8 to 9 bismuth salicylate tablets divided 3 times daily imposes a significant
                pill burden on an older patient population that frequently takes multiple medications. For these reasons,
                the AGA has conditionally recommended bismuth salicylate as a second-line alternative treatment that may
                be appropriate for select patients who have contraindications to corticosteroids or for whom cost is a determining
                factor.
            </p>
            <div class="textbox shadow cRounded bgComment inner articleTextbox" id="dtbox5">
                <div class="caption">&nbsp;</div>
                <div class="textbox-body">
                    <div class="content">
                        <p><strong>Recommendation 5. In patients with symptomatic microscopic colitis in whom budesonide therapy is not feasible, the AGA suggests treatment with prednisolone (or prednisone) over no treatment for the induction of clinical remission. <em>Conditional recommendation, very low quality of evidence.</em></strong></p>
                    </div>
                    <div class="textbox-tail">
                        <div class="referencesWrapper" id="">
                            <div id="references">&nbsp;</div>
                        </div>
                    </div>
                </div>
            </div>
            <p>A very small randomized clinical trial showed a 22% clinical response rate among 9 patients in the intervention
                arm, whereas none of the 3 patients in the control arm exhibited a response. Due to serious imprecision and
                risk of bias, the clinical benefit of systemic corticosteroids is uncertain. Despite the paucity of evidence,
                the panel considered that systemic prednisolone would likely reduce clinical symptoms given the indirect
                evidence of the effectiveness of budesonide. Although the quality of the evidence for safety data was also
                very low, extensive clinical experience with systemic corticosteroids for other conditions suggests that
                the risk of adverse events is significant. The AGA offers a conditional recommendation for the use of systemic
                corticosteroids because of the uncertain balance between clinical benefit and potential harm. Although in
                most cases it should not be used as first-line therapy, there may be circumstances in which it may be the
                preferred agent. Prednisolone may be considered in patients who have refractory symptoms after treatment
                with budesonide and when other coexisting etiologies such as celiac disease have been excluded. Moreover,
                because prednisolone is considerably less expensive than budesonide, it may be an alternative choice when
                the cost of the latter is prohibitive.</p>
            <div class="textbox shadow cRounded bgComment inner articleTextbox" id="dtbox6">
                <div class="caption">&nbsp;</div>
                <div class="textbox-body">
                    <div class="content">
                        <p><strong>Recommendation 6. In patients with symptomatic microscopic colitis, the AGA suggests against combination therapy with cholestyramine and mesalamine over mesalamine alone for the induction of clinical remission</strong>.
                            <strong><em>Conditional recommendation, low quality of evidence.</em></strong></p>
                    </div>
                    <div class="textbox-tail">
                        <div class="referencesWrapper" id="">
                            <div id="references">&nbsp;</div>
                        </div>
                    </div>
                </div>
            </div>
            <p>Low-quality evidence from a single randomized clinical trial failed to show incremental clinical benefit from
                the addition of cholestyramine to mesalamine therapy. In providing a conditional recommendation against combination
                therapy with cholestyramine and mesalamine, the AGA considered not only the uncertain balance between benefits
                and harms but also the feasibility of taking cholestyramine, which can interfere with the administration
                of other medications, especially in an older population in which polypharmacy is commonplace. The panel is
                not able to comment on the appropriateness of cholestyramine monotherapy in the absence of clinical trials
                that have evaluated that intervention.</p>
            <div class="textbox shadow cRounded bgComment inner articleTextbox" id="dtbox7">
                <div class="caption">&nbsp;</div>
                <div class="textbox-body">
                    <div class="content">
                        <p><strong>Recommendation 7. In patients with symptomatic microscopic colitis, the AGA suggests against treatment with Boswellia serrata over no treatment for the induction of clinical remission. <em>Conditional recommendation, low quality of evidence</em></strong></p>
                    </div>
                    <div class="textbox-tail">
                        <div class="referencesWrapper" id="">
                            <div id="references">&nbsp;</div>
                        </div>
                    </div>
                </div>
            </div>
            <p>In a single randomized controlled trial, 44% of 16 patients treated with Boswellia serrata improved clinically
                compared with 27% of 15 patients in the placebo arm, and there was no difference in quality of life between
                the 2 groups. Adverse events were more frequent. All outcomes were not statistically significant. In addition
                to the uncertainty of the balance between benefits and risks, the panel also had concerns regarding the feasibility
                of access to a standardized formulation of Boswellia serrata given the numerous products available. For these
                reasons, the AGA provides a conditional recommendation against its routine use for the treatment of microscopic
                colitis.
            </p>
            <div class="textbox shadow cRounded bgComment inner articleTextbox" id="dtbox8">
                <div class="caption">&nbsp;</div>
                <div class="textbox-body">
                    <div class="content">
                        <p><strong>Recommendation 8. In patients with symptomatic microscopic colitis, the AGA suggests against treatment with probiotics over no treatment for the induction of clinical remission</strong>.
                            <strong><em>Conditional recommendation, low quality of evidence.</em></strong></p>
                    </div>
                    <div class="textbox-tail">
                        <div class="referencesWrapper" id="">
                            <div id="references">&nbsp;</div>
                        </div>
                    </div>
                </div>
            </div>
            <p>Low-quality evidence from a small randomized trial comparing a probiotic (<em>Lactobacillus acidophilus, Bifidobacterium animalis,</em>                and <em>lactis</em> strains) with no treatment showed uncertain benefit with respect to clinical remission,
                histological response, and quality of life due to serious imprecision. Due to the uncertain balance between
                benefit and harm, the AGA provides a conditional recommendation against the use of probiotics. The panel
                acknowledges the uncertainty to which the findings from one trial of a specific probiotic formulation can
                be generalized to the panoply of probiotic products available.</p>
            <div class="textbox shadow cRounded bgComment inner articleTextbox" id="dtbox9">
                <div class="caption">&nbsp;</div>
                <div class="textbox-body">
                    <div class="content">
                        <p><strong>Recommendation 9. For patients with recurrence of symptoms following discontinuation of induction therapy for microscopic colitis, the AGA recommends budesonide for maintenance of clinical remission. <em>Strong recommendation, moderate quality of evidence.</em></strong></p>
                    </div>
                    <div class="textbox-tail">
                        <div class="referencesWrapper" id="">
                            <div id="references">&nbsp;</div>
                        </div>
                    </div>
                </div>
            </div>
            <p>Moderate-quality evidence from 2 randomized clinical trials showed that maintenance therapy with budesonide 6&nbsp;mg
                daily over 6 months resulted in a 66% lower relative risk of clinical relapse (relative risk, 0.34; 95% confidence
                interval, 0.19&ndash;0.6). This regimen also effectively maintained histological response and quality of
                life. A lower dose of budesonide (3 mg daily alternating with 6 mg daily) over 12&nbsp;months showed similar
                efficacy in maintaining clinical response. The panel would like to emphasize that maintenance therapy should
                only be offered to patients with microscopic colitis who have had a clinical relapse after cessation of induction
                therapy. Up to one-third of patients may not require maintenance therapy. Although maintenance dosing of
                budesonide may start at 6 mg, in clinical practice, it is commonly tapered to the lowest effective dose.
                Cessation of maintenance therapy can be considered after 6&nbsp;to 12 months. Although the systemic bioavailability
                of budesonide is low, prolonged use may predispose to bone loss. Thus, osteoporosis prevention and screening
                should be considered in patients who require maintenance therapy.</p>
            <section id="sec1">
                <h2 class="sectionTitle">Summary</h2>
                <div class="content">
                    <p>These actionable recommendations for the medical management of microscopic colitis (<a class="figureLink"
                            href="#tbl3" id="back-tbl3">Table 3</a><span class="hidden crossref-label"><span class="tbl3">Table 3</span></span>)
                        were developed under the framework of the GRADE methodology and were consistent with the Institute
                        of Medicine&rsquo;s Standards for Developing Trustworthy Clinical Practice Guidelines. This guideline
                        is intended to reduce practice variation and promote high-value care. The weight of evidence supports
                        the first-line use of budesonide for induction and, when appropriate, maintenance therapy. Because
                        the technical review and guideline focused on treatments assessed in clinical trials, it did not
                        address the full armamentarium of therapies currently used in practice. We would endorse clinical
                        trials that more rigorously assess the effectiveness of lower-cost alternatives such as antidiarrheal
                        agents (eg,&nbsp;loperamide) and cholestyramine monotherapy with accompanying cost-effective analyses.
                        The role of combination therapies has yet to fully explored. Due to the absence of clinical trial
                        data, this guideline did not address medical treatment of corticosteroid-refractory microscopic colitis.
                        Very limited evidence from case series, however, suggests&nbsp;that immunosuppressants such as azathioprine
                        and anti&ndash;tumor necrosis factor agents may benefit these patients.<span class="bibRef"><sup><a class="layerTrigger layerTriggerClick" href="javascript:void(0);" id="back-bib5">5</a></sup><span class="hoverLayer refLayer"><span aria-label="close window" class="closeBtn" role="button" tabindex="0">x</span>
                        <span class="refLabel">5</span><span class="reference"><span class="refAuthors">Pardi, D.S., Loftus, E.V. Jr., Tremaine, W.J. et al. </span>
                        <span class="refTitle">Treatment of&nbsp;refractory microscopic colitis with azathioprine and&nbsp;6-mercaptopurine.
                                </span><span class="refSeriesTitle">Gastroenterology</span>.
                        <span
                            class="refSeriesDate">2001</span>;
                            <span class="refSeriesVolume">120</span>: <span class="refPages">1483&ndash;1484</span><br />
                            <br />
                            <a href="/servlet/linkout?suffix=e_1_5_1_2_5_2&amp;dbid=4&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=10.1053%2Fgast.2001.23976&amp;cf=abstract&amp;site=ygast-site"
                                onclick="newWindow(this.href);return false">Abstract</a> | <a href="/servlet/linkout?suffix=e_1_5_1_2_5_2&amp;dbid=4&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=10.1053%2Fgast.2001.23976&amp;cf=fulltext&amp;site=ygast-site"
                                onclick="newWindow(this.href);return false">Full Text</a> | <a href="/servlet/linkout?suffix=e_1_5_1_2_5_2&amp;dbid=4&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=10.1053%2Fgast.2001.23976&amp;cf=pdf&amp;site=ygast-site"
                                onclick="newWindow(this.href);return false">Full Text PDF</a> | <a href="/servlet/linkout?suffix=e_1_5_1_2_5_2&amp;dbid=8&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=11313319&amp;cf="
                                onclick="newWindow(this.href);return false">PubMed</a></span><a class="allReferencesLink" href="#references">See all References</a></span>
                            </span><sup>,</sup> <span class="bibRef"><sup><a class="layerTrigger layerTriggerClick" href="javascript:void(0);" id="back-bib6">6</a></sup><span class="hoverLayer refLayer"><span aria-label="close window" class="closeBtn" role="button" tabindex="0">x</span>
                            <span class="refLabel">6</span><span class="reference"><span class="refAuthors">Esteve, M., Mahadevan, U., Sainz, E. et al. </span>
                            <span class="refTitle">Efficacy of anti-TNF therapies in refractory severe microscopic colitis. </span>
                            <span class="refSeriesTitle">J&nbsp;Crohns Colitis</span>. <span class="refSeriesDate">2011</span>;
                            <span class="refSeriesVolume">5</span>:
                            <span class="refPages">612&ndash;618</span><br />
                            <br />
                            <a href="/servlet/linkout?suffix=e_1_5_1_2_6_2&amp;dbid=8&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=22115383&amp;cf="
                                onclick="newWindow(this.href);return false">PubMed</a> | <a href="/servlet/linkout?suffix=e_1_5_1_2_6_2&amp;dbid=137438953472&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=2-s2.0-82255191888&amp;cf="
                                onclick="newWindow(this.href);return false">Scopus (35)</a></span><a class="allReferencesLink"
                                href="#references">See all References</a></span>
                            </span><sup>,</sup> <span class="bibRef"><sup><a class="layerTrigger layerTriggerClick" href="javascript:void(0);" id="back-bib7">7</a></sup><span class="hoverLayer refLayer"><span aria-label="close window" class="closeBtn" role="button" tabindex="0">x</span>
                            <span class="refLabel">7</span><span class="reference"><span class="refAuthors">M&uuml;nch, A., Ignatova, S., and Str&ouml;m, M. </span>
                            <span class="refTitle">Adalimumab in budesonide and methotrexate refractory collagenous colitis.
                                                    </span><span class="refSeriesTitle">Scand J Gastroenterol</span>.
                            <span class="refSeriesDate">2012</span>; <span class="refSeriesVolume">47</span>: <span class="refPages">59&ndash;63</span><br
                            />
                            <br />
                            <a href="/servlet/linkout?suffix=e_1_5_1_2_7_2&amp;dbid=16&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=10.3109%2F00365521.2011.639079&amp;cf="
                                onclick="newWindow(this.href);return false">Crossref</a> | <a href="/servlet/linkout?suffix=e_1_5_1_2_7_2&amp;dbid=8&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=22149977&amp;cf="
                                onclick="newWindow(this.href);return false">PubMed</a> | <a href="/servlet/linkout?suffix=e_1_5_1_2_7_2&amp;dbid=137438953472&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=2-s2.0-84055184713&amp;cf="
                                onclick="newWindow(this.href);return false">Scopus (31)</a></span>
                            <a class="allReferencesLink" href="#references">See all References</a>
                            </span>
                            </span><sup>,</sup> <span class="bibRef"><sup><a class="layerTrigger layerTriggerClick" href="javascript:void(0);" id="back-bib8">8</a></sup><span class="hoverLayer refLayer"><span aria-label="close window" class="closeBtn" role="button" tabindex="0">x</span>
                            <span class="refLabel">8</span><span class="reference"><span class="refAuthors">Pola, S., Fahmy, M., Evans, E. et al. </span>
                            <span class="refTitle">Successful use of infliximab in the treatment of corticosteroid
                                                                    dependent collagenous colitis. </span>
                            <span
                                class="refSeriesTitle">Am J Gastroenterol</span>.
                                <span class="refSeriesDate">2013</span>; <span class="refSeriesVolume">108</span>:
                                <span class="refPages">857&ndash;858</span><br />
                                <br />
                                <a href="/servlet/linkout?suffix=e_1_5_1_2_8_2&amp;dbid=16&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=10.1038%2Fajg.2013.43&amp;cf="
                                    onclick="newWindow(this.href);return false">Crossref</a>                                | <a href="/servlet/linkout?suffix=e_1_5_1_2_8_2&amp;dbid=8&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=23644970&amp;cf="
                                    onclick="newWindow(this.href);return false">PubMed</a> | <a href="/servlet/linkout?suffix=e_1_5_1_2_8_2&amp;dbid=137438953472&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=2-s2.0-84877250648&amp;cf="
                                    onclick="newWindow(this.href);return false">Scopus (11)</a></span>
                                <a class="allReferencesLink" href="#references">See all References</a>
                                </span>
                                </span><sup>,</sup> <span class="bibRef"><sup><a class="layerTrigger layerTriggerClick" href="javascript:void(0);" id="back-bib9">9</a></sup><span class="hoverLayer refLayer"><span aria-label="close window" class="closeBtn" role="button" tabindex="0">x</span>
                                <span class="refLabel">9</span><span class="reference"><span class="refAuthors">M&uuml;nch, A., Fernandez-Banares, F., and Munck, L.K. </span>
                                <span class="refTitle">Azathioprine and mercaptopurine in the management
                                                                                of patients with chronic, active microscopic
                                                                                colitis. </span>
                                <span
                                    class="refSeriesTitle">Aliment Pharmacol Ther</span>.
                                    <span class="refSeriesDate">2013</span>;
                                    <span class="refSeriesVolume">37</span>:
                                    <span class="refPages">795&ndash;798</span><br />
                                    <br />
                                    <a href="/servlet/linkout?suffix=e_1_5_1_2_9_2&amp;dbid=16&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=10.1111%2Fapt.12261&amp;cf="
                                        onclick="newWindow(this.href);return false">Crossref</a>                                    | <a href="/servlet/linkout?suffix=e_1_5_1_2_9_2&amp;dbid=8&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=23432370&amp;cf="
                                        onclick="newWindow(this.href);return false">PubMed</a> | <a href="/servlet/linkout?suffix=e_1_5_1_2_9_2&amp;dbid=137438953472&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=2-s2.0-84875219777&amp;cf="
                                        onclick="newWindow(this.href);return false">Scopus (15)</a></span>
                                    <a class="allReferencesLink" href="#references">See all References</a>
                                    </span>
                                    </span> We encourage prospective clinical trials to further investigate these early findings.</p>
                    <div class="floatDisplay">
                        <div class="table-wrap" id="tbl3">
                            <table>
                                <caption tabindex="0"><span class="label">Table&nbsp;3</span><span>Summary of Recommendations of the AGA Guideline on the Medical Management of Microscopic Colitis</span></caption>
                                <tbody>
                                    <tr>
                                        <th scope="col">Statement</th>
                                        <th scope="col">Strength of recommendation</th>
                                        <th scope="col">Quality of evidence</th>
                                    </tr>
                                    <tr>
                                        <td>Recommendation 1. In patients with symptomatic microscopic colitis, the AGA recommends
                                            treatment with budesonide over no treatment for the induction of clinical remission.</td>
                                        <td>Strong</td>
                                        <td>Moderate</td>
                                    </tr>
                                    <tr>
                                        <td>Recommendation 2. In patients with symptomatic microscopic colitis, the AGA recommends
                                            treatment with budesonide over mesalamine for the induction of clinical remission.</td>
                                        <td>Strong</td>
                                        <td>High</td>
                                    </tr>
                                    <tr>
                                        <td>Recommendation 3. In patients with symptomatic microscopic colitis in whom budesonide
                                            therapy is not feasible, the AGA suggests treatment with mesalamine over no treatment
                                            for the induction of clinical remission.</td>
                                        <td>Conditional</td>
                                        <td>Moderate</td>
                                    </tr>
                                    <tr>
                                        <td>Recommendation 4. In patients with symptomatic microscopic colitis in whom budesonide
                                            therapy is not feasible, the AGA suggests treatment with bismuth salicylate over
                                            no treatment for the induction of clinical remission.</td>
                                        <td>Conditional</td>
                                        <td>Low</td>
                                    </tr>
                                    <tr>
                                        <td>Recommendation 5. In patients with symptomatic microscopic colitis in whom budesonide
                                            therapy is not feasible, the AGA suggests treatment with prednisolone (or prednisone)
                                            over no treatment for the induction of clinical remission.</td>
                                        <td>Conditional</td>
                                        <td>Very low</td>
                                    </tr>
                                    <tr>
                                        <td>Recommendation 6. In patients with symptomatic microscopic colitis, the AGA suggests
                                            against combination therapy with cholestyramine and mesalamine over mesalamine
                                            alone for the induction of clinical remission.</td>
                                        <td>Conditional</td>
                                        <td>Low</td>
                                    </tr>
                                    <tr>
                                        <td>Recommendation 7. In patients with symptomatic microscopic colitis, the AGA suggests
                                            against treatment with Boswellia serrata over no treatment for the induction
                                            of clinical remission.</td>
                                        <td>Conditional</td>
                                        <td>Low</td>
                                    </tr>
                                    <tr>
                                        <td>Recommendation 8. In patients with symptomatic microscopic colitis, the AGA suggests
                                            against treatment with probiotics over no treatment for the induction of clinical
                                            remission.
                                        </td>
                                        <td>Conditional</td>
                                        <td>Low</td>
                                    </tr>
                                    <tr>
                                        <td>Recommendation 9. For patients with recurrence of symptoms following discontinuation
                                            of induction therapy for microscopic colitis, the AGA recommends budesonide for
                                            maintenance of clinical remission.</td>
                                        <td>Strong</td>
                                        <td>Moderate</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </div>
            </section>
        </div>
        <section id="Acknowledgments">
            <h2 class="sectionTitle">Acknowledgments</h2>
            <div class="content">
                <p>The AGA Institute Clinical Guidelines Committee included Steven L. Flamm (Northwestern Feinberg School of
                    Medicine, Chicago, IL), Lauren Gerson (California Pacific Medical Center, San Francisco, CA), Ikuo Hirano
                    (Northwestern University School of Medicine, Chicago, IL), Joel H. Rubenstein (Veterans Affairs Center
                    for Clinical Management Research, Ann Arbor, MI, and Division of Gastroenterology, University of Michigan
                    Medical School, Ann Arbor, MI), Siddharth Singh (Division of Gastroenterology and Hepatology, Mayo Clinic,
                    Rochester, MN), Neil Stollman (University of California San Francisco, Northern California Gastroenterology
                    Consultants, San Francisco, CA), Shahnaz Sultan (Minneapolis VA Health Care System, University of Minnesota,
                    Minneapolis, MN), Sachin B. Wani (University of Colorado, Aurora, CO), David S. Weinberg (Department
                    of Medicine, Fox Chase Cancer Center, Philadelphia, PA), and Yu-Xiao Yang (Division of Gastroenterology,
                    Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA).</p>
            </div>
        </section>
    </div>
    <div class="referencesWrapper" id="cebib0010">
        <div id="references">
            <h2 class="sectionTitle">References</h2>
        </div>
        <ol class="referenceList">
            <li id="bib1"><span class="reference" id="sref1"><span class="refAuthors">Pardi, D.S., Tremaine, W.J., and Carrasco-Labra, A. </span>
                <span class="refTitle">American Gastroenterological Association institute technical review on the medical management of microscopic
                    colitis. </span><span class="refSeriesTitle">Gastroenterology</span>. <span class="refSeriesDate">2016</span>;
                <span class="refSeriesVolume">150</span>: <span class="refPages">247&ndash;274</span> </span>
                <ul class="actionList horizontal">
                    <li><span class="reference" id="sref1"><a href="#back-bib1">View in Article</a>&nbsp;</span></li>
                    <li><span class="reference" id="sref1">| <a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=4&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=10.1053%2Fj.gastro.2015.11.006&amp;cf=abstract&amp;site=ygast-site" onclick="newWindow(this.href);return false">Abstract</a></span></li>
                    <li><span class="reference" id="sref1">| <a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=4&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=10.1053%2Fj.gastro.2015.11.006&amp;cf=fulltext&amp;site=ygast-site" onclick="newWindow(this.href);return false">Full Text</a></span></li>
                    <li><span class="reference" id="sref1">| <a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=4&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=10.1053%2Fj.gastro.2015.11.006&amp;cf=pdf&amp;site=ygast-site" onclick="newWindow(this.href);return false">Full Text PDF</a></span></li>
                    <li><span class="reference" id="sref1">| <a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=137438953472&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=2-s2.0-84952685034&amp;cf=" onclick="newWindow(this.href);return false">Scopus (2)</a></span></li>
                </ul>
            </li>
            <li id="bib2">AGA Institute clinical practice guideline development process. <a href="http://www.gastro.org/guidelines/guidelines-policies">http://www.gastro.org/guidelines/guidelines-policies</a>.</li>
            <li id="bib3"><span class="reference" id="sref3"><span class="refAuthors">Graham, R., Mancher, M., Wolman, D.M. et al. </span>
                <span class="refTitle">Clinical practice guidelines we can trust. </span><span class="refPublisherName">Institute of Medicine; The National Academies Press</span>,
                <span class="refPublisherLoc">Washington, DC</span>; <span class="refDate">2011</span></span>
                <ul class="actionList horizontal">
                    <li><span class="reference" id="sref3"><a href="#back-bib3">View in Article</a>&nbsp;</span></li>
                </ul>
            </li>
            <li id="bib4"><span class="reference" id="sref4"><span class="refAuthors">Sultan, S., Falck-Ytter, Y., and Inadomi, J.M. </span>
                <span class="refTitle">The AGA Institute process for developing clinical practice guidelines part one: grading the evidence. </span>
                <span class="refSeriesTitle">Clin Gastroenterol Hepatol</span>. <span class="refSeriesDate">2013</span>;
                <span class="refSeriesVolume">11</span>:
                <span class="refPages">329&ndash;332</span></span>
                <ul class="actionList horizontal">
                    <li><span class="reference" id="sref4"><a href="#back-bib4">View in Article</a>&nbsp;</span></li>
                    <li><span class="reference" id="sref4">| <a href="/servlet/linkout?suffix=e_1_5_1_2_4_2&amp;dbid=4&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=10.1016%2Fj.cgh.2013.02.001&amp;cf=abstract&amp;site=yjcgh-site" onclick="newWindow(this.href);return false">Abstract</a></span></li>
                    <li><span class="reference" id="sref4">| <a href="/servlet/linkout?suffix=e_1_5_1_2_4_2&amp;dbid=4&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=10.1016%2Fj.cgh.2013.02.001&amp;cf=fulltext&amp;site=yjcgh-site" onclick="newWindow(this.href);return false">Full Text</a></span></li>
                    <li><span class="reference" id="sref4">| <a href="/servlet/linkout?suffix=e_1_5_1_2_4_2&amp;dbid=4&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=10.1016%2Fj.cgh.2013.02.001&amp;cf=pdf&amp;site=yjcgh-site" onclick="newWindow(this.href);return false">Full Text PDF</a></span></li>
                    <li><span class="reference" id="sref4">| <a href="/servlet/linkout?suffix=e_1_5_1_2_4_2&amp;dbid=8&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=23517554&amp;cf=" onclick="newWindow(this.href);return false">PubMed</a></span></li>
                    <li><span class="reference" id="sref4">| <a href="/servlet/linkout?suffix=e_1_5_1_2_4_2&amp;dbid=137438953472&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=2-s2.0-84875317616&amp;cf=" onclick="newWindow(this.href);return false">Scopus (17)</a></span></li>
                </ul>
            </li>
            <li id="bib5"><span class="reference" id="sref5"><span class="refAuthors">Pardi, D.S., Loftus, E.V. Jr., Tremaine, W.J. et al. </span>
                <span class="refTitle">Treatment of&nbsp;refractory microscopic colitis with azathioprine and&nbsp;6-mercaptopurine. </span>
                <span class="refSeriesTitle">Gastroenterology</span>. <span class="refSeriesDate">2001</span>; <span class="refSeriesVolume">120</span>:
                <span class="refPages">1483&ndash;1484</span></span>
                <ul class="actionList horizontal">
                    <li><span class="reference" id="sref5"><a href="#back-bib5">View in Article</a>&nbsp;</span></li>
                    <li><span class="reference" id="sref5">| <a href="/servlet/linkout?suffix=e_1_5_1_2_5_2&amp;dbid=4&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=10.1053%2Fgast.2001.23976&amp;cf=abstract&amp;site=ygast-site" onclick="newWindow(this.href);return false">Abstract</a></span></li>
                    <li><span class="reference" id="sref5">| <a href="/servlet/linkout?suffix=e_1_5_1_2_5_2&amp;dbid=4&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=10.1053%2Fgast.2001.23976&amp;cf=fulltext&amp;site=ygast-site" onclick="newWindow(this.href);return false">Full Text</a></span></li>
                    <li><span class="reference" id="sref5">| <a href="/servlet/linkout?suffix=e_1_5_1_2_5_2&amp;dbid=4&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=10.1053%2Fgast.2001.23976&amp;cf=pdf&amp;site=ygast-site" onclick="newWindow(this.href);return false">Full Text PDF</a></span></li>
                    <li><span class="reference" id="sref5">| <a href="/servlet/linkout?suffix=e_1_5_1_2_5_2&amp;dbid=8&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=11313319&amp;cf=" onclick="newWindow(this.href);return false">PubMed</a></span></li>
                </ul>
            </li>
            <li id="bib6"><span class="reference" id="sref6"><span class="refAuthors">Esteve, M., Mahadevan, U., Sainz, E. et al. </span>
                <span class="refTitle">Efficacy of anti-TNF therapies in refractory severe microscopic colitis. </span>
                <span
                    class="refSeriesTitle">J&nbsp;Crohns Colitis</span>.
                    <span class="refSeriesDate">2011</span>; <span class="refSeriesVolume">5</span>: <span class="refPages">612&ndash;618</span></span>
                    <ul class="actionList horizontal">
                        <li><span class="reference" id="sref6"><a href="#back-bib6">View in Article</a>&nbsp;</span></li>
                        <li><span class="reference" id="sref6">| <a href="/servlet/linkout?suffix=e_1_5_1_2_6_2&amp;dbid=8&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=22115383&amp;cf=" onclick="newWindow(this.href);return false">PubMed</a></span></li>
                        <li><span class="reference" id="sref6">| <a href="/servlet/linkout?suffix=e_1_5_1_2_6_2&amp;dbid=137438953472&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=2-s2.0-82255191888&amp;cf=" onclick="newWindow(this.href);return false">Scopus (35)</a></span></li>
                    </ul>
            </li>
            <li id="bib7"><span class="reference" id="sref7"><span class="refAuthors">M&uuml;nch, A., Ignatova, S., and Str&ouml;m, M. </span>
                <span class="refTitle">Adalimumab in budesonide and methotrexate refractory collagenous colitis. </span>
                <span
                    class="refSeriesTitle">Scand J Gastroenterol</span>.
                    <span class="refSeriesDate">2012</span>; <span class="refSeriesVolume">47</span>: <span class="refPages">59&ndash;63</span>                    </span>
                    <ul class="actionList horizontal">
                        <li><span class="reference" id="sref7"><a href="#back-bib7">View in Article</a>&nbsp;</span></li>
                        <li><span class="reference" id="sref7">| <a href="/servlet/linkout?suffix=e_1_5_1_2_7_2&amp;dbid=16&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=10.3109%2F00365521.2011.639079&amp;cf=" onclick="newWindow(this.href);return false">Crossref</a></span></li>
                        <li><span class="reference" id="sref7">| <a href="/servlet/linkout?suffix=e_1_5_1_2_7_2&amp;dbid=8&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=22149977&amp;cf=" onclick="newWindow(this.href);return false">PubMed</a></span></li>
                        <li><span class="reference" id="sref7">| <a href="/servlet/linkout?suffix=e_1_5_1_2_7_2&amp;dbid=137438953472&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=2-s2.0-84055184713&amp;cf=" onclick="newWindow(this.href);return false">Scopus (31)</a></span></li>
                    </ul>
            </li>
            <li id="bib8"><span class="reference" id="sref8"><span class="refAuthors">Pola, S., Fahmy, M., Evans, E. et al. </span>
                <span class="refTitle">Successful use of infliximab in the treatment of corticosteroid dependent collagenous colitis. </span>
                <span class="refSeriesTitle">Am J Gastroenterol</span>. <span class="refSeriesDate">2013</span>; <span class="refSeriesVolume">108</span>:
                <span class="refPages">857&ndash;858</span> </span>
                <ul class="actionList horizontal">
                    <li><span class="reference" id="sref8"><a href="#back-bib8">View in Article</a>&nbsp;</span></li>
                    <li><span class="reference" id="sref8">| <a href="/servlet/linkout?suffix=e_1_5_1_2_8_2&amp;dbid=16&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=10.1038%2Fajg.2013.43&amp;cf=" onclick="newWindow(this.href);return false">Crossref</a></span></li>
                    <li><span class="reference" id="sref8">| <a href="/servlet/linkout?suffix=e_1_5_1_2_8_2&amp;dbid=8&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=23644970&amp;cf=" onclick="newWindow(this.href);return false">PubMed</a></span></li>
                    <li><span class="reference" id="sref8">| <a href="/servlet/linkout?suffix=e_1_5_1_2_8_2&amp;dbid=137438953472&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=2-s2.0-84877250648&amp;cf=" onclick="newWindow(this.href);return false">Scopus (11)</a></span></li>
                </ul>
            </li>
            <li id="bib9"><span class="reference" id="sref9"><span class="refAuthors">M&uuml;nch, A., Fernandez-Banares, F., and Munck, L.K. </span>
                <span class="refTitle">Azathioprine and mercaptopurine in the management of patients with chronic, active microscopic colitis. </span>
                <span class="refSeriesTitle">Aliment Pharmacol Ther</span>. <span class="refSeriesDate">2013</span>;
                <span
                    class="refSeriesVolume">37</span>:
                    <span class="refPages">795&ndash;798</span></span>
                    <ul class="actionList horizontal">
                        <li><span class="reference" id="sref9"><a href="#back-bib9">View in Article</a>&nbsp;</span></li>
                        <li><span class="reference" id="sref9">| <a href="/servlet/linkout?suffix=e_1_5_1_2_9_2&amp;dbid=16&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=10.1111%2Fapt.12261&amp;cf=" onclick="newWindow(this.href);return false">Crossref</a></span></li>
                        <li><span class="reference" id="sref9">| <a href="/servlet/linkout?suffix=e_1_5_1_2_9_2&amp;dbid=8&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=23432370&amp;cf=" onclick="newWindow(this.href);return false">PubMed</a></span></li>
                        <li><span class="reference" id="sref9">| <a href="/servlet/linkout?suffix=e_1_5_1_2_9_2&amp;dbid=137438953472&amp;doi=10.1053/j.gastro.2015.11.008&amp;key=2-s2.0-84875219777&amp;cf=" onclick="newWindow(this.href);return false">Scopus (15)</a></span></li>
                    </ul>
            </li>
        </ol>
    </div>
</div>